 SEATTLE, Dec. 02, 2021 GLOBE NEWSWIRE -- Adaptive Biotechnologies Corporation Nasdaq: ADPT, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, together with its collaborators will present data from more than 30 abstracts demonstrating the utility of Adaptives next-generation sequencing NGS-based clonoSEQ Assay in assessing minimal residual disease MRD in blood cancer patients at the 63rd Annual Meeting of the American Society of Hematology ASH, December 11-14. 